Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
Hazard Ratio01:12

Hazard Ratio

69
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
69
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

37
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
37
Relative Risk01:12

Relative Risk

93
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
93

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative Estimation of Clinical Intrasubject Variability of a Pharmacokinetic Parameter.

The AAPS journal·2026
Same author

Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

Some Common Dose-Exposure-Response Estimands and Conditions for Their Causal Identifiability.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Latent Variable Indirect Response Modeling of Cendakimab Exposure-Response for Longitudinal Dysphagia Days Using a Combined Uniform-Binomial Likelihood Framework.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B.

Clinical pharmacokinetics·2025
Same author

Operating Characteristics of the Simulated Healthy Participant Approach in Impaired Clearance Studies.

The AAPS journal·2025
Same journal

Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Butorphanol Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework.

CPT: pharmacometrics & systems pharmacology·2026
See all related articles

Related Experiment Video

Updated: May 13, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection.

Yeamin Huh1, Ruolun Qiu2, John Prybylski1

  • 1Pfizer Research and Development, Pfizer Inc, Groton, Connecticut, USA.

CPT: Pharmacometrics & Systems Pharmacology
|May 12, 2025
PubMed
Summary
This summary is machine-generated.

Ritlecitinib demonstrates a favorable safety profile for alopecia areata (AA) treatment. Exposure-response analyses confirm minimal risk of QTc prolongation and lymphopenia, supporting the 50mg non-loading dose for adults and adolescents.

Keywords:
modeling and simulationpharmacokinetic‐pharmacodynamicpopulation analysis

More Related Videos

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications
08:46

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Published on: April 21, 2022

2.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Related Experiment Videos

Last Updated: May 13, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications
08:46

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Published on: April 21, 2022

2.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Area of Science:

  • Pharmacology
  • Clinical Safety
  • Drug Development

Background:

  • Ritlecitinib, a kinase inhibitor, is approved for alopecia areata (AA).
  • The pivotal Phase 2b/3 study evaluated various dosing regimens.
  • Understanding the safety profile is crucial for optimal dose selection.

Purpose of the Study:

  • To characterize the safety profile of ritlecitinib using exposure-response (ER) analyses.
  • To inform dose selection for AA treatment in adults and adolescents.
  • To assess potential safety risks across different patient subgroups.

Main Methods:

  • Developed a concentration-QTc model to assess cardiac safety.
  • Utilized a semi-mechanistic PK/PD model for lymphocyte profiles.
  • Employed Poisson regression to analyze adverse event incidence (infections, rash) based on exposure.

Main Results:

  • No evidence of ritlecitinib-induced QTc prolongation was found.
  • Ritlecitinib showed a marginal decrease in lymphocytes, with low predicted Grade 3/4 lymphopenia, except for a slight increase with loading dose.
  • Increased incidence of infections and rash was dose-dependent but not disproportionately large within the studied range.

Conclusions:

  • The safety ER relationship for ritlecitinib is consistent across patient subgroups, including adolescents.
  • No unique safety risks were identified in adolescent patients.
  • Comprehensive safety ER analysis supports the 50mg non-loading dose regimen for ritlecitinib in AA patients.